


Image

1647



PATENT  
Docket No. 350292001300

**CERTIFICATE OF HAND DELIVERY**

I hereby certify that this correspondence is being hand filed with the United States Patent and Trademark Office in Alexandria, Virginia, on November 13, 2003.

Diana Gidish (htc1)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In the application of:

Masaaki KOSAKA et al.

Serial No.: 10/069,290

Filing Date: February 25, 2002

For: EXPRESSION ENHANCER FOR HM  
1.24 ANTIGEN

Examiner: To be assigned

Group Art Unit: To be assigned

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR 1.97 & 1.98**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Pursuant to 37 CFR 1.97 and 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This Supplemental Information Disclosure Statement is submitted before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.


Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 CFR 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the event that the transmittal letter is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 350292001300. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.


Dated: November 13, 2003

Respectfully submitted,

By:   
Barry E. Bretschneider  
Registration No. 28,055

Morrison & Foerster LLP  
1650 Tysons Boulevard  
Suite 300  
McLean, Virginia 22102  
Telephone: (703) 760-7743  
Facsimile: (703) 760-7777

<b>Form PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>	Docket Number 350292001300	Application Number 10/069,290
	Applicant <b>Masaaki KOSAKA et al.</b>	
	Filing Date February 25, 2002	Group Art Unit to be assigned
	Mailing Date November 7, 2003	



## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO

## OTHER DOCUMENTS

*(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
	1.	Goto et al. "A Novel Membrane Antigen Selectively Expressed on Terminally Differentiated Human B Cells" Blood, Vol. 84, No. 5, 9/1999, pp. 1922-1930.
	2.	Kosaka et al. "Advances in Biology and Pathogenesis of Multiple Myeloma" Japanese Clinical Vol. 53, No. 3, 3/1995, pp. 627-635.
	3.	Ozaki et al. "Humanized Anti-HM1.24 Antibody Mediates Myeloma Cell Cytotoxicity That Is Enhanced by Cytokine Stimulation of Effector Cells" Blood, Vol. 93, No. 11, 6/1999, pp. 3922-3930.
	4.	Pestka et al. "Interferons and Their Actions" Am. Rev. Biochem. Vol. 56, 1987, pp. 727-777.
	5.	Langer et al. "Interferon Receptors" Immunology Today, Vol. 9, No. 12, 1988, pp. 393-400.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.